We did not observe any significant changes in the levels of secreted TGFβ1 when Arl4c was knocked down in the cancer cells themselves, further confirming that this effect of Arl4c on promoting tumor stemness and drug resistance depends on its role in PSCs. The gene discussed is ARL4C; the disease is neoplasm.